1. Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)
- Author
-
Benjamin Meyer, Johan Reimerink, Giulia Torriani, Fion Brouwer, Gert-Jan Godeke, Sabine Yerly, Marieke Hoogerwerf, Nicolas Vuilleumier, Laurent Kaiser, Isabella Eckerle, and Chantal Reusken
- Subjects
SARS-CoV-2 ,neutralising antibodies ,surrogate virus neutralisation assay ,pseudovirus neutralisation assay ,cell-based virus neutralisation assay ,Infectious and parasitic diseases ,RC109-216 ,Microbiology ,QR1-502 - Abstract
ABSTRACTTo understand SARS-CoV-2 immunity after natural infection or vaccination, functional assays such as virus neutralising assays are needed. So far, assays to detect SARS-CoV-2 neutralising antibodies rely on cell-culture based infection assays either using wild type SARS-CoV-2 or pseudotyped viruses. Such assays are labour-intensive, require appropriate biosafety facilities and are difficult to standardize. Recently, a new surrogate virus neutralisation test (sVNT) was described that uses the principle of an ELISA to measure the neutralisation capacity of anti-SARS-CoV-2 antibodies directed against the receptor binding domain. Here, we performed an independent evaluation of the robustness, specificity and sensitivity on an extensive panel of sera from 269 PCR-confirmed COVID-19 cases and 259 unmatched samples collected before 2020 and compared it to cell-based neutralisation assays. We found a high specificity of 99.2 (95%CI: 96.9–99.9) and overall sensitivity of 80.3 (95%CI: 74.9–84.8) for the sVNT. Clinical sensitivity increased between early (14 dpos/dpd) from 75.0 (64.7–83.2) to 83.1 (76.5–88.1). Also, higher severity was associated with an increase in clinical sensitivity. Upon comparison with cell-based neutralisation assays we determined an analytical sensitivity of 74.3 (56.4–86.9) and 98.2 (89.4–99.9) for titres ≥10 to
- Published
- 2020
- Full Text
- View/download PDF